<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00306384</url>
  </required_header>
  <id_info>
    <org_study_id>SYR-322-OLE-012</org_study_id>
    <secondary_id>2005-004672-20</secondary_id>
    <secondary_id>U1111-1113-8455</secondary_id>
    <nct_id>NCT00306384</nct_id>
  </id_info>
  <brief_title>Long-term Safety of Alogliptin in Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Long-Term, Open-Label Extension Study to Investigate the Long-Term Safety of SYR110322 (SYR-322) in Subjects With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the long-term safety of alogliptin, once daily (QD),
      following participation in 1 of 7 controlled studies in patients with type 2 diabetes
      mellitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SYR-322 (alogliptin) is an inhibitor of the dipeptidyl peptidase IV enzyme. Dipeptidyl
      peptidase IV is thought to be primarily responsible for the degradation of 2 peptide hormones
      released in response to nutrient ingestion, namely glucagon-like peptide-1 and
      glucose-dependent insulinotropic peptide. It is expected that inhibition of dipeptidyl
      peptidase IV will improve glycemic (glucose) control in patients with type 2 diabetes
      mellitus by prolonging the beneficial effects of glucagon-like peptide-1.

      The rising incidence of type 2 diabetes mellitus and the limitations of the currently
      available treatments suggest the need for new therapies for glycemic control. Studies have
      been undertaken in humans that evaluated the effects of directly augmenting glucagon-like
      peptide-1 and glucose-dependent insulinotropic peptide levels and of inhibiting the activity
      of dipeptidyl peptidase IV.

      This study is an extension of 7 controlled phase 3 studies of alogliptin. These phase 3
      studies included 1 monotherapy study of alogliptin (SYR-322-PLC-010; NCT00286455); 4
      placebo-controlled add-on studies of alogliptin, namely in combination with a sulfonylurea
      (SYR-322-SULF-007; NCT00286468), metformin (SYR-322-MET-008; NCT00286442), a
      thiazolidinedione (pioglitazone; SYR-322-TZD-009; NCT00286494), and insulin (SYR-322-INS-011;
      NCT00286429); 1 coadministration study with pioglitazone in combination with metformin
      (01-05-TL-322OPI-001; NCT00328627), and 1 coadministration study with pioglitazone
      (01-06-TL-322OPI-002; NCT00395512).

      The end of treatment or early withdrawal visit from the preceding study will be the screening
      visit for this study, after which enrolled patients will be required to commit to
      approximately 22 additional visits at the study center.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>4 years</time_frame>
    <description>Safety was assessed by physical examinations, clinical laboratory parameters, electrocardiogram (ECG) readings, vital sign measurements, oral temperature, and hypoglycemic events. Changes in laboratory values or ECG parameters were considered to be adverse events if they were judged to be clinically significant. A TEAE was any event that started on or after the first dose of open-label study drug and within 14 days after the last dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Over Time in Glycosylated Hemoglobin</measure>
    <time_frame>Baseline and Month 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42 and 45.</time_frame>
    <description>The change from Baseline in glycosylated hemoglobin (HbA1c; the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) during the study. Endpoint was defined as the last postbaseline observation collected within 7 days after the last dose of open-label study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose</measure>
    <time_frame>Baseline and Year 4</time_frame>
    <description>The change from Baseline in fasting plasma glucose (FPG) at the last post-baseline observation, collected within 7 days after the last dose of open-label study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Marked Hyperglycemia</measure>
    <time_frame>Randomization up to 4 years.</time_frame>
    <description>Marked Hyperglycemia is defined as fasting plasma glucose greater than or equal to 200 mg/dL (≥11.10 mmol/L).
The Month 42 to Month 45 interval includes all marked hyperglycemic episodes occurring on or after Day 1247 (a 203-day visit window).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Proinsulin Level</measure>
    <time_frame>Baseline and Year 4</time_frame>
    <description>Proinsulin is a precursor to insulin, and was measured as an indicator of pancreatic function. The change from Baseline in fasting proinsulin to the last post-baseline observation, collected within 7 days after the last dose of open-label study drug.
Note: A transcription error occurred in the reporting of 1 proinsulin value for a patient in the alogliptin 25 mg completed group, for whom a partial patient ID number was mistakenly entered as an end-of-treatment proinsulin level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Insulin Level</measure>
    <time_frame>Baseline and Year 4</time_frame>
    <description>The change from Baseline in fasting insulin at the last post-baseline observation, collected within 7 days after the last dose of open-label study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in C-peptide Level</measure>
    <time_frame>Baseline and Year 4</time_frame>
    <description>C-peptide is a byproduct created when the hormone insulin is produced and is measured by a blood test. Change from Baseline to the last post-baseline observation, collected within 7 days after the last dose of open-label study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight</measure>
    <time_frame>Baseline and Year 4</time_frame>
    <description>Change from Baseline in body weight to the last post-baseline observation collected within 7 days after the last dose of open-label study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Clinical Response</measure>
    <time_frame>Weeks 2, 4, 8, 12, every 3 months up to 4 years, and 1 Day after final dose.</time_frame>
    <description>Clinical response was defined based on the absolute value of HbA1c meeting one of two clinical targets at any post-baseline visit:
HbA1c ≤6.5%;
HbA1c ≤7.0%.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3323</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Alogliptin 12.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alogliptin 12.5 tablet, orally, once daily for up to 4 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alogliptin 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alogliptin 25 mg tablet, orally, once daily for up to 4 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alogliptin</intervention_name>
    <description>Alogliptin tablets.</description>
    <arm_group_label>Alogliptin 12.5 mg</arm_group_label>
    <arm_group_label>Alogliptin 25 mg</arm_group_label>
    <other_name>SYR110322</other_name>
    <other_name>SYR-322</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females of childbearing potential who are sexually active must agree to use adequate
             contraception, and can neither be pregnant nor lactating from Screening throughout the
             duration of the study.

          -  Type 2 diabetes mellitus and was enrolled in one of the following 7 controlled Phase
             III studies. The study will be open to all patients who completed one of these studies
             through the end-of-treatment visit:

               -  SYR-322-PLC-010 - NCT00286455

               -  SYR-322-SULF-007 - NCT00286468

               -  SYR-322-MET-008 - NCT00286442

               -  SYR-322-TZD-009 - NCT00286494

               -  SYR-322-INS-011 - NCT00286429

               -  01-05-TL-322OPI-001 - NCT00328627

               -  01-06-TL-322OPI-002 - NCT00395512

          -  Alanine aminotransferase less than or equal to 3 times the upper limit of normal and
             serum creatinine less than or equal to 2.0 mg per dL.

          -  Able and willing to monitor own blood glucose concentrations with a home glucose
             monitor.

          -  No major illness or debility that in the investigator's opinion prohibits the patient
             from completing the study.

        Exclusion Criteria

          -  The occurrence of any adverse event or condition during the controlled Phase III
             studies, which, in the opinion of the investigator, should exclude the patient from
             participating in the open-label extension.

          -  Is required to take or intends to continue taking any disallowed medication, any
             prescription medication, herbal treatment or over-the counter medication that may
             interfere with evaluation of the study medication, including:

               -  Weight-loss drugs

               -  Investigational antidiabetics, additional dipeptidyl peptidase-4 (DPP-4) and
                  glucagon-like peptide-1 (GLP 1) inhibitors

               -  Incretin Mimetics,

               -  Oral or systemically injected glucocorticoids.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>VP Biological Sciences</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Artesia</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orange</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Longwood</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Port Richie</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ocoee</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Cloud</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Avon</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elkhart</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Erlanger</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sudbury</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burlington</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pinehurst</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnatti</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lansdale</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Grove</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Simpsonville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cookeville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milan</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Texarkana</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <state>La Plata</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <state>Moron</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rosario</city>
        <state>Sante Fe</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ciudadd Autonoma de Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mar del Plata</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fortaleza</city>
        <state>Ceara</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Curitiba</city>
        <state>Parana</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mogi das Cruzes</city>
        <state>Sao Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santos</city>
        <state>Sao Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ostrava</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sternberk</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zlin</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santo Domingo Oeste</city>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aschaffenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nuremberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Schwerin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Witten</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guatemala</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Almere</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>De Bilt</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Geleen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oud-Beijerland</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zwijndrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bellavista</city>
        <state>Lima</state>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Isidro</city>
        <state>Lima</state>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ica</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bytom</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kamieniec Zabkowicki</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leczyca</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Radom</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Somerset West</city>
        <state>Western Cape</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Parow</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Chile</country>
    <country>Czech Republic</country>
    <country>Dominican Republic</country>
    <country>Germany</country>
    <country>Guatemala</country>
    <country>Netherlands</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>India</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Spain</country>
  </removed_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2006</study_first_submitted>
  <study_first_submitted_qc>March 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2006</study_first_posted>
  <results_first_submitted>February 17, 2013</results_first_submitted>
  <results_first_submitted_qc>February 17, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 22, 2013</results_first_posted>
  <last_update_submitted>February 17, 2013</last_update_submitted>
  <last_update_submitted_qc>February 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glucose Metabolism Disorder</keyword>
  <keyword>Dysmetabolic Syndrome</keyword>
  <keyword>Type II Diabetes</keyword>
  <keyword>Diabetes Mellitus,</keyword>
  <keyword>Lipoatrophic</keyword>
  <keyword>Dyslipidemia</keyword>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alogliptin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients who completed 1 of the following 7 studies took part in the study at 423 investigative sites worldwide: SYR-322-PLC-010 (NCT00286455); SYR-322-SULF-007 (NCT00286468); SYR-322-MET-008 (NCT00286442); SYR-322-TZD-009 (NCT00286494); SYR-322-INS-011 (NCT00286429); 01-05-TL-322OPI-001 (NCT00328627); 01-06-TL-322OPI-002 (NCT00395512).</recruitment_details>
      <pre_assignment_details>Patients who had previously completed 1 of 7 double-blind alogliptin studies were randomized (1:1) to either 12.5 or 25 mg once daily alogliptin. Patients who were rescued during their previous double-blind study in response to protocol-defined hyperglycemic rescue criteria were assigned to alogliptin 25 mg.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Alogliptin 12.5 mg</title>
          <description>Participants who completed the previous double-blind study received alogliptin 12.5 tablet, orally, once daily for up to 4 years.</description>
        </group>
        <group group_id="P2">
          <title>Alogliptin 25 mg</title>
          <description>Participants who completed the previous double-blind study received alogliptin 25 mg tablets orally, once daily for up to 4 years.</description>
        </group>
        <group group_id="P3">
          <title>Rescued: Alogliptin 25 mg</title>
          <description>Participants rescued from the previous double-blind study received alogliptin 25 mg tablets, orally once daily for up to 4 years.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1396"/>
                <participants group_id="P2" count="1399"/>
                <participants group_id="P3" count="528"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Set</title>
              <participants_list>
                <participants group_id="P1" count="1395">Patients who received at least one dose of study drug</participants>
                <participants group_id="P2" count="1398">Patients who received at least one dose of study drug</participants>
                <participants group_id="P3" count="527">Patients who received at least one dose of study drug</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="854"/>
                <participants group_id="P2" count="891"/>
                <participants group_id="P3" count="251"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="542"/>
                <participants group_id="P2" count="508"/>
                <participants group_id="P3" count="277"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
                <participants group_id="P2" count="87"/>
                <participants group_id="P3" count="40"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Major protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="35"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Voluntary withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="199"/>
                <participants group_id="P2" count="187"/>
                <participants group_id="P3" count="91"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study termination</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="38"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator discretion</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="70"/>
                <participants group_id="P3" count="32"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site closure</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Alogliptin 12.5 mg</title>
          <description>Participants who completed the previous double-blind study received alogliptin 12.5 tablet, orally, once daily for up to 4 years.</description>
        </group>
        <group group_id="B2">
          <title>Alogliptin 25 mg</title>
          <description>Participants who completed the previous double-blind study received alogliptin 25 mg tablets orally, once daily for up to 4 years.</description>
        </group>
        <group group_id="B3">
          <title>Rescued: Alogliptin 25 mg</title>
          <description>Participants rescued from the previous double-blind study received alogliptin 25 mg tablets, orally once daily for up to 4 years.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1396"/>
            <count group_id="B2" value="1399"/>
            <count group_id="B3" value="528"/>
            <count group_id="B4" value="3323"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.8" spread="9.92"/>
                    <measurement group_id="B2" value="55.1" spread="10.21"/>
                    <measurement group_id="B3" value="53.0" spread="10.06"/>
                    <measurement group_id="B4" value="55.0" spread="10.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1134"/>
                    <measurement group_id="B2" value="1134"/>
                    <measurement group_id="B3" value="461"/>
                    <measurement group_id="B4" value="2729"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="262"/>
                    <measurement group_id="B2" value="265"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="594"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="699"/>
                    <measurement group_id="B2" value="730"/>
                    <measurement group_id="B3" value="289"/>
                    <measurement group_id="B4" value="1718"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="697"/>
                    <measurement group_id="B2" value="669"/>
                    <measurement group_id="B3" value="239"/>
                    <measurement group_id="B4" value="1605"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1025"/>
                    <measurement group_id="B2" value="1007"/>
                    <measurement group_id="B3" value="390"/>
                    <measurement group_id="B4" value="2422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="176"/>
                    <measurement group_id="B2" value="193"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.42" spread="5.370"/>
                    <measurement group_id="B2" value="31.71" spread="5.266"/>
                    <measurement group_id="B3" value="32.20" spread="5.704"/>
                    <measurement group_id="B4" value="31.66" spread="5.386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes duration</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.56" spread="5.446"/>
                    <measurement group_id="B2" value="6.92" spread="5.824"/>
                    <measurement group_id="B3" value="8.35" spread="6.325"/>
                    <measurement group_id="B4" value="6.99" spread="5.784"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous double-blind study treatment</title>
          <description>Patients from coadministration Studies 01-05-TL-322OPI-001 and 01-06-TL-322OPI-002 are presented separately; due to the complexity of treatment assignments, they were not included in the subgroups of patients previously randomized to placebo, alogliptin 12.5 mg, or alogliptin 25 mg.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="135"/>
                    <measurement group_id="B4" value="363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alogliptin 12.5 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="274"/>
                    <measurement group_id="B2" value="262"/>
                    <measurement group_id="B3" value="105"/>
                    <measurement group_id="B4" value="641"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alogliptin 25 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="243"/>
                    <measurement group_id="B2" value="262"/>
                    <measurement group_id="B3" value="99"/>
                    <measurement group_id="B4" value="604"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study 01-05-TL-322OPI-001</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="546"/>
                    <measurement group_id="B2" value="548"/>
                    <measurement group_id="B3" value="146"/>
                    <measurement group_id="B4" value="1240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study 01-06-TL-322OPI-002</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="215"/>
                    <measurement group_id="B2" value="217"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="475"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)</title>
        <description>Safety was assessed by physical examinations, clinical laboratory parameters, electrocardiogram (ECG) readings, vital sign measurements, oral temperature, and hypoglycemic events. Changes in laboratory values or ECG parameters were considered to be adverse events if they were judged to be clinically significant. A TEAE was any event that started on or after the first dose of open-label study drug and within 14 days after the last dose.</description>
        <time_frame>4 years</time_frame>
        <population>Safety set</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 12.5 mg</title>
            <description>Participants who completed the previous double-blind study received alogliptin 12.5 tablet, orally, once daily for up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg</title>
            <description>Participants who completed the previous double-blind study received alogliptin 25 mg tablets orally, once daily for up to 4 years.</description>
          </group>
          <group group_id="O3">
            <title>Rescued: Alogliptin 25 mg</title>
            <description>Participants rescued from the previous double-blind study received alogliptin 25 mg tablets, orally once daily for up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)</title>
          <description>Safety was assessed by physical examinations, clinical laboratory parameters, electrocardiogram (ECG) readings, vital sign measurements, oral temperature, and hypoglycemic events. Changes in laboratory values or ECG parameters were considered to be adverse events if they were judged to be clinically significant. A TEAE was any event that started on or after the first dose of open-label study drug and within 14 days after the last dose.</description>
          <population>Safety set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1394"/>
                <count group_id="O2" value="1399"/>
                <count group_id="O3" value="527"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any treatment emergent adverse event (TEAE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.2"/>
                    <measurement group_id="O2" value="87.1"/>
                    <measurement group_id="O3" value="84.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study drug-related TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.6"/>
                    <measurement group_id="O2" value="22.7"/>
                    <measurement group_id="O3" value="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0"/>
                    <measurement group_id="O2" value="6.1"/>
                    <measurement group_id="O3" value="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment emergent serious AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="16.3"/>
                    <measurement group_id="O3" value="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study drug-related serious AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6"/>
                    <measurement group_id="O2" value="2.1"/>
                    <measurement group_id="O3" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-emergent deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="1.0"/>
                    <measurement group_id="O3" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Over Time in Glycosylated Hemoglobin</title>
        <description>The change from Baseline in glycosylated hemoglobin (HbA1c; the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) during the study. Endpoint was defined as the last postbaseline observation collected within 7 days after the last dose of open-label study drug.</description>
        <time_frame>Baseline and Month 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42 and 45.</time_frame>
        <population>Safety set where data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 12.5 mg</title>
            <description>Participants who completed the previous double-blind study received alogliptin 12.5 tablet, orally, once daily for up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg</title>
            <description>Participants who completed the previous double-blind study received alogliptin 25 mg tablets orally, once daily for up to 4 years.</description>
          </group>
          <group group_id="O3">
            <title>Rescued: Alogliptin 25 mg</title>
            <description>Participants rescued from the previous double-blind study received alogliptin 25 mg tablets, orally once daily for up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Over Time in Glycosylated Hemoglobin</title>
          <description>The change from Baseline in glycosylated hemoglobin (HbA1c; the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) during the study. Endpoint was defined as the last postbaseline observation collected within 7 days after the last dose of open-label study drug.</description>
          <population>Safety set where data were available.</population>
          <units>percent glycosylated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1395"/>
                <count group_id="O2" value="1398"/>
                <count group_id="O3" value="527"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=1362, 1359, 501)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.21" spread="0.815"/>
                    <measurement group_id="O2" value="7.22" spread="0.814"/>
                    <measurement group_id="O3" value="9.30" spread="0.900"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 change from Baseline (n=1290, 1286, 463)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.635"/>
                    <measurement group_id="O2" value="0.14" spread="0.632"/>
                    <measurement group_id="O3" value="-0.52" spread="1.064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 change from Baseline (n= 1236, 1252, 433)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31" spread="0.859"/>
                    <measurement group_id="O2" value="0.26" spread="0.848"/>
                    <measurement group_id="O3" value="-0.73" spread="1.285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 change from Baseline (n=1217, 1231, 413)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34" spread="0.969"/>
                    <measurement group_id="O2" value="0.33" spread="0.894"/>
                    <measurement group_id="O3" value="-0.78" spread="1.282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 change from Baseline (1175, 1182, 388)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" spread="1.010"/>
                    <measurement group_id="O2" value="0.41" spread="0.952"/>
                    <measurement group_id="O3" value="-0.78" spread="1.309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 15 change from Baseline (n=1119, 1133, 374)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47" spread="0.990"/>
                    <measurement group_id="O2" value="0.48" spread="1.068"/>
                    <measurement group_id="O3" value="-0.75" spread="1.332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18 change from Baseline (n=1111, 1095, 350)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="1.082"/>
                    <measurement group_id="O2" value="0.50" spread="1.047"/>
                    <measurement group_id="O3" value="-0.70" spread="1.320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 21 change from Baseline (n=1061, 1071, 338)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" spread="1.096"/>
                    <measurement group_id="O2" value="0.51" spread="1.070"/>
                    <measurement group_id="O3" value="-0.75" spread="1.389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 change from Baseline (n=1027, 1039, 320)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" spread="1.111"/>
                    <measurement group_id="O2" value="0.58" spread="1.107"/>
                    <measurement group_id="O3" value="-0.69" spread="1.417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 27 change from Baseline (n=991, 1002, 300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" spread="1.124"/>
                    <measurement group_id="O2" value="0.58" spread="1.159"/>
                    <measurement group_id="O3" value="-0.71" spread="1.349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 30 change from Baseline (n=944, 955, 281)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.57" spread="1.127"/>
                    <measurement group_id="O2" value="0.57" spread="1.167"/>
                    <measurement group_id="O3" value="-0.78" spread="1.361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 33 change from Baseline (n=923, 941, 276)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55" spread="1.181"/>
                    <measurement group_id="O2" value="0.57" spread="1.196"/>
                    <measurement group_id="O3" value="-0.73" spread="1.418"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 change from Baseline (n=882, 931, 274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" spread="1.215"/>
                    <measurement group_id="O2" value="0.55" spread="1.141"/>
                    <measurement group_id="O3" value="-0.80" spread="1.411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 39 change from Baseline (n=886, 913, 259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" spread="1.223"/>
                    <measurement group_id="O2" value="0.56" spread="1.216"/>
                    <measurement group_id="O3" value="-0.73" spread="1.431"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 42 change from Baseline (n=854, 891, 252)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.59" spread="1.225"/>
                    <measurement group_id="O2" value="0.54" spread="1.221"/>
                    <measurement group_id="O3" value="-0.78" spread="1.492"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 45 change from Baseline (n=866, 902, 253)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.61" spread="1.250"/>
                    <measurement group_id="O2" value="0.56" spread="1.242"/>
                    <measurement group_id="O3" value="-0.70" spread="1.398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint change from Baseline (n=1362, 1359, 501)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" spread="1.310"/>
                    <measurement group_id="O2" value="0.61" spread="1.261"/>
                    <measurement group_id="O3" value="-0.42" spread="1.448"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose</title>
        <description>The change from Baseline in fasting plasma glucose (FPG) at the last post-baseline observation, collected within 7 days after the last dose of open-label study drug.</description>
        <time_frame>Baseline and Year 4</time_frame>
        <population>Safety set where data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 12.5 mg</title>
            <description>Participants who completed the previous double-blind study received alogliptin 12.5 tablet, orally, once daily for up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg</title>
            <description>Participants who completed the previous double-blind study received alogliptin 25 mg tablets orally, once daily for up to 4 years.</description>
          </group>
          <group group_id="O3">
            <title>Rescued: Alogliptin 25 mg</title>
            <description>Participants rescued from the previous double-blind study received alogliptin 25 mg tablets, orally once daily for up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose</title>
          <description>The change from Baseline in fasting plasma glucose (FPG) at the last post-baseline observation, collected within 7 days after the last dose of open-label study drug.</description>
          <population>Safety set where data were available.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1388"/>
                <count group_id="O2" value="1386"/>
                <count group_id="O3" value="517"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144.4" spread="41.64"/>
                    <measurement group_id="O2" value="142.6" spread="39.41"/>
                    <measurement group_id="O3" value="215.3" spread="60.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8" spread="56.25"/>
                    <measurement group_id="O2" value="14.9" spread="53.46"/>
                    <measurement group_id="O3" value="-26.4" spread="84.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Marked Hyperglycemia</title>
        <description>Marked Hyperglycemia is defined as fasting plasma glucose greater than or equal to 200 mg/dL (≥11.10 mmol/L).
The Month 42 to Month 45 interval includes all marked hyperglycemic episodes occurring on or after Day 1247 (a 203-day visit window).</description>
        <time_frame>Randomization up to 4 years.</time_frame>
        <population>Safety set where data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 12.5 mg</title>
            <description>Participants who completed the previous double-blind study received alogliptin 12.5 tablet, orally, once daily for up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg</title>
            <description>Participants who completed the previous double-blind study received alogliptin 25 mg tablets orally, once daily for up to 4 years.</description>
          </group>
          <group group_id="O3">
            <title>Rescued: Alogliptin 25 mg</title>
            <description>Participants rescued from the previous double-blind study received alogliptin 25 mg tablets, orally once daily for up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Marked Hyperglycemia</title>
          <description>Marked Hyperglycemia is defined as fasting plasma glucose greater than or equal to 200 mg/dL (≥11.10 mmol/L).
The Month 42 to Month 45 interval includes all marked hyperglycemic episodes occurring on or after Day 1247 (a 203-day visit window).</description>
          <population>Safety set where data were available.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1395"/>
                <count group_id="O2" value="1398"/>
                <count group_id="O3" value="527"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 to &lt;Week 2 (n=1299, 1290, 481)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1"/>
                    <measurement group_id="O2" value="8.0"/>
                    <measurement group_id="O3" value="55.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 to &lt;Week 4 (n=1286, 1306, 481)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5"/>
                    <measurement group_id="O2" value="10.2"/>
                    <measurement group_id="O3" value="45.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 to &lt;Week 8 (n=1303, 1331, 490)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2"/>
                    <measurement group_id="O2" value="11.0"/>
                    <measurement group_id="O3" value="46.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 to &lt;Week 12 (n=1331, 1347, 495)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5"/>
                    <measurement group_id="O2" value="10.8"/>
                    <measurement group_id="O3" value="41.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 to &lt;Month 6 (n=1329, 1338, 480)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0"/>
                    <measurement group_id="O2" value="11.6"/>
                    <measurement group_id="O3" value="39.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 to &lt;Month 9 (n=1286, 1289, 448)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8"/>
                    <measurement group_id="O2" value="10.7"/>
                    <measurement group_id="O3" value="36.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 to &lt;Month 12 (n=1252, 1260, 425)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4"/>
                    <measurement group_id="O2" value="12.9"/>
                    <measurement group_id="O3" value="32.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 to &lt;Month 15 (n=1210, 1217, 409)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1"/>
                    <measurement group_id="O2" value="13.0"/>
                    <measurement group_id="O3" value="29.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 15 to &lt;Month 18 (n=1157, 1166, 389)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7"/>
                    <measurement group_id="O2" value="13.8"/>
                    <measurement group_id="O3" value="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18 to &lt;Month 21 (n=1128, 1128, 365)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7"/>
                    <measurement group_id="O2" value="11.6"/>
                    <measurement group_id="O3" value="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 21 to &lt;Month 24 (n=1094,1099, 357)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2"/>
                    <measurement group_id="O2" value="11.5"/>
                    <measurement group_id="O3" value="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 to &lt;Month 27 (n=1046, 1066, 334)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6"/>
                    <measurement group_id="O2" value="12.3"/>
                    <measurement group_id="O3" value="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 27 to &lt;Month 30 (n=1010, 1028, 316)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6"/>
                    <measurement group_id="O2" value="11.8"/>
                    <measurement group_id="O3" value="24.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 30 to &lt;Month 33 (n=981, 988, 299)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6"/>
                    <measurement group_id="O2" value="11.7"/>
                    <measurement group_id="O3" value="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 33 to &lt;Month 36 (n=945, 959, 289)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5"/>
                    <measurement group_id="O2" value="12.3"/>
                    <measurement group_id="O3" value="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 to &lt;Month 39 (n=920, 949, 281)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2"/>
                    <measurement group_id="O2" value="12.5"/>
                    <measurement group_id="O3" value="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 39 to &lt;Month 42 (n=899, 934, 267)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.7"/>
                    <measurement group_id="O2" value="13.1"/>
                    <measurement group_id="O3" value="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 42 to Month 45 (n=889, 921, 261)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.5"/>
                    <measurement group_id="O2" value="23.9"/>
                    <measurement group_id="O3" value="39.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall (n= 1389, 1392, 518)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.7"/>
                    <measurement group_id="O2" value="50.7"/>
                    <measurement group_id="O3" value="87.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Proinsulin Level</title>
        <description>Proinsulin is a precursor to insulin, and was measured as an indicator of pancreatic function. The change from Baseline in fasting proinsulin to the last post-baseline observation, collected within 7 days after the last dose of open-label study drug.
Note: A transcription error occurred in the reporting of 1 proinsulin value for a patient in the alogliptin 25 mg completed group, for whom a partial patient ID number was mistakenly entered as an end-of-treatment proinsulin level.</description>
        <time_frame>Baseline and Year 4</time_frame>
        <population>Safety set where data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 12.5 mg</title>
            <description>Participants who completed the previous double-blind study received alogliptin 12.5 tablet, orally, once daily for up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg</title>
            <description>Participants who completed the previous double-blind study received alogliptin 25 mg tablets orally, once daily for up to 4 years.</description>
          </group>
          <group group_id="O3">
            <title>Rescued: Alogliptin 25 mg</title>
            <description>Participants rescued from the previous double-blind study received alogliptin 25 mg tablets, orally once daily for up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Proinsulin Level</title>
          <description>Proinsulin is a precursor to insulin, and was measured as an indicator of pancreatic function. The change from Baseline in fasting proinsulin to the last post-baseline observation, collected within 7 days after the last dose of open-label study drug.
Note: A transcription error occurred in the reporting of 1 proinsulin value for a patient in the alogliptin 25 mg completed group, for whom a partial patient ID number was mistakenly entered as an end-of-treatment proinsulin level.</description>
          <population>Safety set where data were available.</population>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1277"/>
                <count group_id="O2" value="1263"/>
                <count group_id="O3" value="393"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.1" spread="25.99"/>
                    <measurement group_id="O2" value="25.4" spread="30.28"/>
                    <measurement group_id="O3" value="40.2" spread="36.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="27.09"/>
                    <measurement group_id="O2" value="39.7" spread="1243.37"/>
                    <measurement group_id="O3" value="-3.3" spread="31.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Insulin Level</title>
        <description>The change from Baseline in fasting insulin at the last post-baseline observation, collected within 7 days after the last dose of open-label study drug.</description>
        <time_frame>Baseline and Year 4</time_frame>
        <population>Safety set where data was available. Does not include patients enrolled in Protocol 01-05-TL-OPI322-001 or Protocol 01-06-TL-OPI322-002.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 12.5 mg</title>
            <description>Participants who completed the previous double-blind study received alogliptin 12.5 tablet, orally, once daily for up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg</title>
            <description>Participants who completed the previous double-blind study received alogliptin 25 mg tablets orally, once daily for up to 4 years.</description>
          </group>
          <group group_id="O3">
            <title>Rescued: Alogliptin 25 mg</title>
            <description>Participants rescued from the previous double-blind study received alogliptin 25 mg tablets, orally once daily for up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Insulin Level</title>
          <description>The change from Baseline in fasting insulin at the last post-baseline observation, collected within 7 days after the last dose of open-label study drug.</description>
          <population>Safety set where data was available. Does not include patients enrolled in Protocol 01-05-TL-OPI322-001 or Protocol 01-06-TL-OPI322-002.</population>
          <units>μIU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="537"/>
                <count group_id="O2" value="526"/>
                <count group_id="O3" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.19" spread="9.898"/>
                    <measurement group_id="O2" value="15.50" spread="12.608"/>
                    <measurement group_id="O3" value="18.64" spread="15.845"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.45" spread="42.706"/>
                    <measurement group_id="O2" value="2.13" spread="16.496"/>
                    <measurement group_id="O3" value="5.62" spread="23.197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in C-peptide Level</title>
        <description>C-peptide is a byproduct created when the hormone insulin is produced and is measured by a blood test. Change from Baseline to the last post-baseline observation, collected within 7 days after the last dose of open-label study drug.</description>
        <time_frame>Baseline and Year 4</time_frame>
        <population>Safety set where data was available. Patients enrolled in Protocol 01-05-TL-OPI322-001 or Protocol 01-06-TL-OPI322-002 are not included.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 12.5 mg</title>
            <description>Participants who completed the previous double-blind study received alogliptin 12.5 tablet, orally, once daily for up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg</title>
            <description>Participants who completed the previous double-blind study received alogliptin 25 mg tablets orally, once daily for up to 4 years.</description>
          </group>
          <group group_id="O3">
            <title>Rescued: Alogliptin 25 mg</title>
            <description>Participants rescued from the previous double-blind study received alogliptin 25 mg tablets, orally once daily for up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in C-peptide Level</title>
          <description>C-peptide is a byproduct created when the hormone insulin is produced and is measured by a blood test. Change from Baseline to the last post-baseline observation, collected within 7 days after the last dose of open-label study drug.</description>
          <population>Safety set where data was available. Patients enrolled in Protocol 01-05-TL-OPI322-001 or Protocol 01-06-TL-OPI322-002 are not included.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="615"/>
                <count group_id="O2" value="615"/>
                <count group_id="O3" value="322"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.406" spread="1.5115"/>
                    <measurement group_id="O2" value="3.323" spread="1.5945"/>
                    <measurement group_id="O3" value="3.572" spread="1.7531"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.471" spread="1.6464"/>
                    <measurement group_id="O2" value="-0.439" spread="1.2783"/>
                    <measurement group_id="O3" value="-0.641" spread="1.5804"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight</title>
        <description>Change from Baseline in body weight to the last post-baseline observation collected within 7 days after the last dose of open-label study drug.</description>
        <time_frame>Baseline and Year 4</time_frame>
        <population>Safety set for whom data was available.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 12.5 mg</title>
            <description>Participants who completed the previous double-blind study received alogliptin 12.5 tablet, orally, once daily for up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg</title>
            <description>Participants who completed the previous double-blind study received alogliptin 25 mg tablets orally, once daily for up to 4 years.</description>
          </group>
          <group group_id="O3">
            <title>Rescued: Alogliptin 25 mg</title>
            <description>Participants rescued from the previous double-blind study received alogliptin 25 mg tablets, orally once daily for up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight</title>
          <description>Change from Baseline in body weight to the last post-baseline observation collected within 7 days after the last dose of open-label study drug.</description>
          <population>Safety set for whom data was available.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1387"/>
                <count group_id="O2" value="1385"/>
                <count group_id="O3" value="518"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.12" spread="19.376"/>
                    <measurement group_id="O2" value="86.61" spread="19.185"/>
                    <measurement group_id="O3" value="88.62" spread="20.947"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.64" spread="5.283"/>
                    <measurement group_id="O2" value="-0.61" spread="5.428"/>
                    <measurement group_id="O3" value="0.25" spread="5.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Clinical Response</title>
        <description>Clinical response was defined based on the absolute value of HbA1c meeting one of two clinical targets at any post-baseline visit:
HbA1c ≤6.5%;
HbA1c ≤7.0%.</description>
        <time_frame>Weeks 2, 4, 8, 12, every 3 months up to 4 years, and 1 Day after final dose.</time_frame>
        <population>Safety set.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 12.5 mg</title>
            <description>Participants who completed the previous double-blind study received alogliptin 12.5 tablet, orally, once daily for up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg</title>
            <description>Participants who completed the previous double-blind study received alogliptin 25 mg tablets orally, once daily for up to 4 years.</description>
          </group>
          <group group_id="O3">
            <title>Rescued: Alogliptin 25 mg</title>
            <description>Participants rescued from the previous double-blind study received alogliptin 25 mg tablets, orally once daily for up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Clinical Response</title>
          <description>Clinical response was defined based on the absolute value of HbA1c meeting one of two clinical targets at any post-baseline visit:
HbA1c ≤6.5%;
HbA1c ≤7.0%.</description>
          <population>Safety set.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1395"/>
                <count group_id="O2" value="1398"/>
                <count group_id="O3" value="527"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HbA1c ≤6.5%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.8"/>
                    <measurement group_id="O2" value="34.1"/>
                    <measurement group_id="O3" value="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1c ≤7.0%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.1"/>
                    <measurement group_id="O2" value="65.5"/>
                    <measurement group_id="O3" value="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent adverse events (AEs) were defined as any AEs that started on or after the date of the first dose of open-label study drug and within 14 days after the date of the last dose of open-label study drug.</time_frame>
      <desc>At each study visit, the investigator assessed whether any events had occurred. Participants could report events at any other time during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Alogliptin 12.5 mg</title>
          <description>Participants who completed the previous double-blind study received alogliptin 12.5 tablet, orally, once daily for up to 4 years.</description>
        </group>
        <group group_id="E2">
          <title>Alogliptin 25 mg</title>
          <description>Participants who completed the previous double-blind study received alogliptin 25 mg tablets orally, once daily for up to 4 years.</description>
        </group>
        <group group_id="E3">
          <title>Rescued: Alogliptin 25 mg</title>
          <description>Participants rescued from the previous double-blind study received alogliptin 25 mg tablets, orally once daily for up to 4 years.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="233" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="228" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="83" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Coronary artery insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>MELAS syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Retinal vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Iridocyclitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Retinal artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Gastrointestinal hypomotility</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Gastrointestinal necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Hernial eventration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Pancreatitis relapsing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Rectal polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Rectal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Salivary duct inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Perforation bile duct</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Allergy to arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Diabetic foot infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Acquired immunodeficiency syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Coccidioidomycosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Endophthalmitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Giardiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Helicobacter gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Hepatitis A</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Lymphangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Nosocomial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Pneumococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Pneumonia cryptococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Pyoderma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Sialoadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Typhoid fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Wound sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Anaemia postoperative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Foreign body trauma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Incisional hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Traumatic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Chondromalacia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Muscle disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Myopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Tendon calcification</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Breast cancer female</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Ovarian adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Acute leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Adrenal adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of adrenal gland</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Brain neoplasm benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Breast cancer stage I</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Breast cancer stage III</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Carcinoid tumour of the appendix</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Central nervous system neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma stage 0</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Cervix neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Choroid melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Colon cancer stage III</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Focal nodular hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stromal tumour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Haemangioma of liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Langerhans' cell granulomatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Mantle cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Mesothelioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Metastases to peritoneum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Multiple myeloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Neuroendocrine tumour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Oligodendroglioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Ovarian germ cell teratoma benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Prostatic adenom</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Brain stem syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Cerebral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Diabetic mononeuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Facial palsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Normal pressure hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Radial nerve palsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Reversible ischaemic neurological deficit</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Vascular headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous incomplete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Anxiety disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Hypnagogic hallucination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Calculus urethral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Diabetic nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Postrenal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Stress urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Colpocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Genital prolapse</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Breast calcifications</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Epididymal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Fallopian tube cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Menometrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Vocal cord polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Asthmatic crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Skin necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Pelvic venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="876" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="898" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="333" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="115" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="155" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="163" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="71" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="162" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="153" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="133" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="162" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="113" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="132" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="111" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="80" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="118" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="108" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="102" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="111" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="80" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="105" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="207" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="203" subjects_at_risk="1399"/>
                <counts group_id="E3" subjects_affected="85" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sr. VP, Clinical Science</name_or_title>
      <organization>Takeda Global Research and Development Center, Inc.</organization>
      <phone>800-778-2860</phone>
      <email>clinicaltrialregistry@tpna.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

